Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
August 24, 2023 16:00 ET
|
Zealand Pharma
Company announcement – No. 29 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, August 24, 2023 – Zealand Pharma A/S...
Zealand Pharma Announces Financial Results for the First Half of 2023
August 17, 2023 01:00 ET
|
Zealand Pharma
Company announcement - No. 28 / 2023 Zealand Pharma Announces Financial Results for the First Half of 2023 Strong progress across R&D pipeline and significant strengthening of the balance...
Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results
August 14, 2023 11:05 ET
|
Zealand Pharma
Press Release – No. 9 / 2023 Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results Copenhagen, Denmark, August 14, 2023 – a Zealand...
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
July 03, 2023 06:01 ET
|
Zealand Pharma
Company announcement – No. 27 / 2023 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 Doses of 0.6 and 1.2 mg ZP8396...
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
June 30, 2023 13:32 ET
|
Zealand Pharma
Press release – No. 8 / 2023 Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S...
Total number of shares and voting rights in Zealand Pharma at June 30, 2023
June 30, 2023 11:05 ET
|
Zealand Pharma
Company announcement – No. 26 / 2023 Total number of shares and voting rights in Zealand Pharma at June 30, 2023 Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL)...
Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency
June 26, 2023 02:30 ET
|
Zealand Pharma
Press release – No. 7 / 2023 Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency ...
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
June 24, 2023 11:35 ET
|
Zealand Pharma
Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions reached up to a mean...
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
June 23, 2023 17:15 ET
|
Zealand Pharma
Press Release No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
June 08, 2023 16:00 ET
|
Zealand Pharma
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023 – Zealand Pharma A/S (“Zealand”)...